All In Biotech

Drug Trial Radar · NCT02611492

A Phase III Randomized Trial of the Reduction of Chemotherapy in Philadelphia Chromosome-positive ALL of Young Adults

A Phase III Study, Randomized, to Evaluate the Reduction of Chemotherapy Intensity in Association With Nilotinib (Tasigna®) in Philadelphia Chromosome-positive (Ph+) ALL of Young Adults (18-59 Years Old) (GRAAPH-2014)

Last checked: Nov 20, 2026Latest source record: Oct 21, 2019 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingPhase 3. Randomized with 265 participants. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

265

Planned (sponsor's estimate)

Start

Apr 2016

Primary completion

Dec 2020

Study completion Dec 2025

Sponsor

Lead sponsor
Assistance Publique - Hôpitaux de ParisAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Nov 20, 2015

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 59 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The Primary objective is to assess the non-inferiority of the experimental arm (arm B) compared to the control arm (arm A) in terms of Major Molecular Response (MMolR) after the 4th cycle (MRD4) in patients aged 18-59 years old with de novo Philadelphia positive (Ph+) acute lymphoblastic leukemia (ALL)

Conditions

  • Philadelphia Chromosome Positive Adult Acute Lymphoblastic Leukemia

Interventions

  • NilotinibDrug

    400 mg/12h per os D1 to D28 cycles 1-4 300 mg/12h per os D1-D14 interphase

  • MethotrexateDrug

    1 g/m2 continuous Intravenous Infusion (CIV) D1 cycles 2 and 4 25 mg/m2 per os D1, D8 interphase

  • Aracytine (Ara C)Drug

    Age\<45 years: 3 mg/m2/12h D2, D3 cycles 2 and 4 Age\>=45 years: 1.5 mg/m2/12h D2, D3 cycles 2 and 4

  • Granulocyte Colony-Stimulating Factor (G-CSF)Drug

    5µg/kg/d (SC) D6 until neutrophils \> 1 G/L D15 cycles 1 and 3; D6 cycles 2 and 4

  • DepomedrolDrug

    40 mg + methotrexate 15 mg + Aracytine (AraC) 40mg IT cycle 1: D1, D8, D15 IT cycles 2 and 4: D9 IT cycle 3: D1

  • DexamethasoneDrug

    40 mg per os, D1-D2, D8-D9, D15-D16, D22-D23, cycles 1 and 3

  • VincristineDrug

    2 mg total dose IV, D1 D8 D15 D22 cycles 1 and 3

  • ImatinibDrug

    300 mg/12h per os in post-SCT maintenance therapy for during at least 2 years

  • 6 Mercaptopurine (6MP)Drug

    60 mg/m2 per os, D1 to D14, interphase

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Major Molecular Response (MMolR)Time frame: 4 cycles (4 months)

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Hopital Saint Louis

    Paris, France · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.